Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited has issued 1.8 million ordinary shares on the ASX without needing detailed disclosure, as they comply with relevant regulations. The biotechnology company focuses on innovative cancer treatments using their iNKT cell therapy platform from Imperial College London. Their leading product, ALA-101, targets cancer cells and is being developed as a therapy that can be administered from a healthy donor to patients.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
